Artemisinin Market: Market Size & Forecast 2026

Artemisinin and its derivatives form the cornerstone of modern malaria treatment, with the market encompassing both the raw active pharmaceutical ingredient (API) and finished combination therapies. Market size estimates derive from private industry analysis rather than official government statistical agencies, which track public health metrics and procurement volumes but do not publish consolidated revenue figures for this commercial sector.

• •The market includes artemisinin API for pharmaceutical manufacturing and finished artemisinin-based combination therapies (ACTs)
• •Various industry estimates place the 2025 market size between $0.6 billion and $1.2 billion, reflecting different scope definitions
• •WHO monitors global ACT distribution and public procurement volumes but does not publish dollar-denominated market totals

The primary driver remains malaria's persistent public health burden, with the World Health Organization reporting millions of cases annually across endemic regions. Expanding production capacity, particularly in China which dominates Artemisia annua cultivation, combined with sustained donor funding for malaria control programs, supports market expansion.

• •WHO recommends ACTs as first-line treatment for uncomplicated Plasmodium falciparum malaria, sustaining demand
• •Donor-funded procurement through mechanisms like the Global Fund maintains large-scale purchasing in sub-Saharan Africa
• •Agricultural expansion of Artemisia annua and extraction technology improvements increase supply capacity

The market divides into artemisinin API for formulation and finished pharmaceutical products, with the API segment representing a substantial portion of overall value. Geographically, Asia-Pacific, particularly China, dominates cultivation and initial extraction, while Africa represents the largest consumption market driven by malaria epidemiology.

• •Artemisinin API market estimates range from approximately $960 million to over $1.8 billion depending on forecast horizon and scope
• •ACT product segments show varying growth trajectories, with some estimates projecting from $640 million to over $3.6 billion by 2030
• •Sub-Saharan Africa accounts for the majority of ACT consumption, while East and Southeast Asia lead production

What are the recent trends and outlook?

The market faces emerging challenges including artemisinin partial resistance in Southeast Asia, which the WHO tracks closely, prompting research into new formulations and combination partners. Industry projections suggest continued expansion through 2030-2035, though growth rates vary significantly across estimates depending on whether they encompass broader antimalarial markets or focus specifically on artemisinin-based products.

• •WHO monitors artemisinin partial resistance in the Greater Mekong Subregion, influencing treatment guideline updates
• •Market projections through 2035 show CAGR estimates ranging from 5.8% to 15.6%, reflecting methodological differences
• •Research into semisynthetic artemisinin and plant breeding aims to stabilize supply and reduce price volatility